Generate Biomedicines (GENB) shares fell 4.6% in Thursday trading after the company posted a wider-than-expected Q2 net loss and lower revenue.
The company reported Q2 net loss of $0.52 per diluted share, narrowing from a loss of $1.94 a year earlier.
Four analysts surveyed by FactSet expected a loss of $0.50.
Collaboration revenue for the quarter ended June 30 was $6.3 million, down from $10.1 million a year ago.
Three analysts expected $5.5 million.
Price: 13.83, Change: -0.66, Percent Change: -4.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments